The key milestones include: exenatide approval (2005), liraglutide approval (2010), semaglutide injection approval (2017), oral semaglutide with SNAC approval (2019), orforglipron cryo-EM structure published (2020), orforglipron Phase 2 results in NEJM (2023), orforglipron Phase 3 ATTAIN-1 results in NEJM (2025), and FDA regulatory submission (2025)
A map of human type 1 diabetes progression by imaging mass cytometry
The acetyl group provides a plausible protective mechanism
The researchers concluded that intranasal administration of DSIP, given both preventively and therapeutically over 8 days, leads to accelerated recovery of motor functions in SD rats after focal stroke
Key players in the market include Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca, Merck & Co., Bristol-Myers Squibb, and Amgen